Titan Pharmaceuticals Inc. (TTNP)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.59+0.05 (+0.90%)
At close: 4:00 PM EDT
People also watch:
VNDAIMUCBDSINAVBAEZS
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open5.60
Prev Close5.54
Bid5.48 x 400
Ask5.72 x 500
Day's Range5.50 - 5.60
52wk Range0.63 - 10.00
1y Target EstN/A
Market Cap118.5M
P/E Ratio (ttm)18.89
Beta1.42
Volume70,510
Avg Vol (3m)389,407
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research6 days ago

    TTNP: Probuphine Licensing: EU & Australia In the Works

    During a recent call with Titan Pharmaceuticals (TTNP), we spoke with CEO Sunil Bhonsle and discussed the company’s current efforts to license Probuphine outside of the US and Canada.  As we have previously written, Titan and partner Braeburn Pharmaceuticals (Private) received FDA approval for the drug in late May.  Braeburn is responsible for the manufacture and marketing of the drug, and was able to rapidly fill the pipeline and train a substantial number of providers to perform the implantation procedure in the first several weeks following the nod from the FDA.  Within a month, Braeburn made the first sales of Probuphine and Titan began to receive royalties. Titan licensed to Braeburn the rights to sell Probuphine in the United States and Canada, retaining rights to sell the drug in the rest of the world.  Currently, Titan is seeking a meeting with the European Medicines Agency (EMA) to determine what data and efforts are required to gain approval.  The company is employing the services of a consultant and using its internal resources to identify the most efficient route to gain the agency’s assent and to find an appropriate partner to conduct training, marketing and sales.  Currently, Titan expects to meet with the EMA sometime in the fourth quarter.

  • Capital Cube18 days ago

    ETF’s with exposure to Titan Pharmaceuticals, Inc. : August 12, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Titan Pharmaceuticals, Inc. Here are 5 ETF’s with the largest exposure to TTNP-US. Comparing the performance and risk of Titan Pharmaceuticals, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Zacks Small Cap Research19 days ago

    TTNP: Probuphine Sales in 2Q:16; Provider Training On Track

    Titan Pharmaceuticals, Inc. (TTNP) reported 2Q:16 results on August 9, 2016.  $15 million of revenues were reported reflecting the milestone payment for FDA approval of probuphine and approximately $4,000 worth of revenues were generated from royalty payments related to partner Braeburn sales of the drug.  This compares to the second quarter in 2015 where Titan recognized $0.8 million related to an upfront license fee payment.  Diluted earnings per share were $0.55 compared to our estimate of $0.63 and second quarter 2015 loss per share of ($0.11).  Our estimate and actual earnings per share varied due to higher than expected R&D and G&A expenses, combined with a higher than expected diluted share count. Research and development expenditures were $1.7 million for the quarter, down from $1.1 million in the prior year and above our estimate of $1.0 million.  Higher R&D was attributable to development expenses related to the ProNeura platform and increases in employee expenses.  General and administrative expenditures were $1.2 million, up $0.4 million compared to last year’s spend.  This was higher than our $0.9 million estimate.  $0.2 million related to contractual fee obligations for the Probuphine license payment, increases in non-cash stock compensation and employee related costs contributed to the increase.  Net other expense of ($0.1) million consisted primarily of non-cash gains and losses on changes in the fair value of warrants, tax expenses, and interest income.